Direkt zum Inhalt
Merck
  • Yield Optimisation of Hepatitis B Virus Core Particles in E. coli Expression System for Drug Delivery Applications.

Yield Optimisation of Hepatitis B Virus Core Particles in E. coli Expression System for Drug Delivery Applications.

Scientific reports (2017-03-04)
Izzat Fahimuddin Bin Mohamed Suffian, Mitla Garcia-Maya, Paul Brown, Tam Bui, Yuya Nishimura, Amir Rafiq Bin Mohammad Johari Palermo, Chiaki Ogino, Akihiko Kondo, Khuloud T Al-Jamal
ZUSAMMENFASSUNG

An E. coli expression system offers a mean for rapid, high yield and economical production of Hepatitis B Virus core (HBc) particles. However, high-level production of HBc particles in bacteria is demanding and optimisation of HBc particle yield from E. coli is required to improve laboratory-scale productivity for further drug delivery applications. Production steps involve bacterial culture, protein isolation, denaturation, purification and finally protein assembly. In this study, we describe a modified E. coli based method for purifying HBc particles and compare the results with those obtained using a conventional purification method. HBc particle morphology was confirmed by Atomic Force Microscopy (AFM). Protein specificity and secondary structure were confirmed by Western Blot and Circular Dichroism (CD), respectively. The modified method produced ~3-fold higher yield and greater purity of wild type HBc particles than the conventional method. Our results demonstrated that the modified method produce a better yield and purity of HBc particles in an E. coli-expression system, which are fully characterised and suitable to be used for drug delivery applications.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Hepatitis-B-Virus-Antikörper (Kernantigen [ayw], Klon 10E11, a.a. 2-10), ascites fluid, clone 10E11, Chemicon®